SCHEMBL11983230

SCHEMBL11983230

COc1ccc2c(c1)c(OC(C)=O)c(C(=O)Nc1ccccc1)c(=O)n2C

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 9/20 0.64
▸ EGFR P00533 8/20 0.64
▸ AHR P35869 1/20 0.52
▸ MAPT P10636 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MAOB P27338 1/20 0.48
▸ FGFR1 P11362 1/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ HIF1A Q16665 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15154449 0.91 EGFR (0.53) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL15154730 0.91 SRC (0.53) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL11983181 0.90 SRC (0.56) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL11983179 0.89 SRC (0.56) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL15154591 0.88 SMN1; SMN2 (0.62) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL15154447 0.88 SRC (0.60) SRCEGFRMAPTFGFR1NPC1
SCHEMBL15154337 0.87 SRC (0.58) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL15154511 0.87 MAPT (0.53) SRCEGFRAHRMAPTSMN1; SMN2
SCHEMBL15154212 0.86 SRC (0.64) SRCEGFRSMN1; SMN2FGFR1NPC1
SCHEMBL15154348 0.86 EGFR (0.64) SRCEGFRMAPTSMN1; SMN2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962598-B2 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators IMMUNAHR AB (SE) 2015-02-24 — — US claimed
EP-2627638-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. Immunahr AB (SE) 2013-08-21 — — EP claimed
US-20130203703-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS IMMUNAHR AB (SE) 2013-08-08 — — US claimed
WO-2012050500-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS. PETTERSSON LARS (SE) 2012-04-19 — — WO claimed
US-8962598-B2 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators IMMUNAHR AB (SE) 2015-02-24 — — US disclosed
US-20130203703-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS IMMUNAHR AB (SE) 2013-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203703-A1 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS AHR, HRH4, ARNT SRC 2173/4885EGFR 826/4885AHR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback